Shane Olwill - Feb 24, 2023 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PIRS)

Role
Chief Development Officer
Signature
/s/ Ahmed Mousa, Attorney-in-fact
Stock symbol
PIRS
Transactions as of
Feb 24, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 04:23 PM
Previous filing
Feb 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PIRS Stock Option (Right to buy) Award $0 +249K $0.00 249K Feb 24, 2023 Common Stock 249K $1.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the option shares on February 24, 2024 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.